Skip to main content
ALGORAE PHARMACEUTICALS LIMITED logo

ALGORAE PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · 1AI ISIN · AU0000296022 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,159 across all filing types
Latest filing 2012-02-27 Interim / Quarterly Rep…
Country AU Australia
Listing ASX 1AI

About ALGORAE PHARMACEUTICALS LIMITED

https://algoraepharma.com/

Algorae Pharmaceuticals Limited is a biopharmaceutical company focused on the discovery and development of novel therapeutic solutions for complex medical conditions. The company leverages its proprietary artificial intelligence platform, AlgoraeOS, to streamline the drug discovery process and identify synergistic drug combinations. Its research pipeline primarily targets neurodegenerative diseases and other areas of high unmet clinical need. Key development programs include AI-116, a combination therapy aimed at treating dementia and Alzheimer's disease. By integrating advanced computational modeling with traditional pharmacological research, the company seeks to accelerate the transition of candidates from preclinical stages to clinical trials, optimizing therapeutic efficacy and safety profiles.

Recent filings

Filing Released Lang Actions
Half Yearly Report and Accounts 24 pages 781.7KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4D Half yearly report' and references the financial period ended 31 December 2011, indicating it is a report for a half-year period. It contains detailed financial data such as revenue, profit/loss, net tangible asset backing, and a comprehensive Directors' Report including business review, financial review, and liquidity information. The document also includes consolidated financial statements and an independent auditor's report. The length of the document (15,000 characters) and the presence of substantive financial data and analysis confirm it is a full interim financial report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2012
2012-02-27 English
LCT completes pre-clinical studies of NTCELL in Parkinson`s 2 pages 36.1KB
Regulatory Filings Classification · 95% confidence The document is a company announcement dated 28 February 2012 from Living Cell Technologies Limited. It reports the completion of pre-clinical studies for a treatment (NTCELL) for Parkinson's disease and outlines future plans for clinical trials. The content focuses on scientific and developmental progress rather than financial results, regulatory filings, or shareholder matters. There are no financial statements, earnings data, or regulatory compliance details. The document is a news release about research progress and upcoming clinical trial plans, which fits the category of a general company announcement or regulatory filing rather than a formal financial or governance report. Given the absence of financial data or formal report structure, the best classification is Regulatory Filings (RNS), which serves as a fallback for miscellaneous company announcements that do not fit other categories.
2012-02-27 English
LCT granted E.U. Patent for tissue engineering 2 pages 35.8KB
Regulatory Filings Classification · 95% confidence The document is a company announcement dated 28 February 2012 about Living Cell Technologies Limited receiving formal notification of an EU patent grant. It discusses the patent details, the company's business activities, and includes forward-looking statements. There are no financial statements, no regulatory filings, no meeting materials, no voting results, no management or board changes, no earnings data, no legal proceedings, no capital or financing updates, and no other report types mentioned. The document is a press release style announcement about a patent grant, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2012-02-27 English
Price query response 3 pages 93.1KB
Regulatory Filings Classification · 100% confidence The document is a letter from the Australian Securities Exchange (ASX) to Living Cell Technologies Limited regarding a price query about recent trading activity and price changes in the company's securities. The company responds to the ASX's questions confirming no undisclosed information exists that could explain the price change and confirms compliance with ASX Listing Rules. The content is a regulatory compliance communication related to market disclosure obligations and trading rules, not a financial report, earnings release, or any other specific report type. It is a regulatory filing responding to a market query, fitting the Regulatory Filings (RNS) category as a general regulatory announcement and compliance document.
2012-02-15 English
LCT granted USA Patent for Auckland Island Pigs 3 pages 38.2KB
Regulatory Filings Classification · 95% confidence The document is a company announcement dated 1 February 2012 about Living Cell Technologies Limited being granted a U.S. patent. It discusses the patent details, the company's business activities, and forward-looking statements. There are no financial statements, regulatory certifications, or detailed financial performance data. The content is an announcement of a patent grant, which is a regulatory or corporate announcement rather than a financial report or management discussion. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a report publication announcement since it does not mention any report being published or attached. The best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous corporate announcements that do not fit other categories.
2012-02-01 English
Becoming a substantial holder 16 pages 447.0KB
Regulatory Filings
2012-01-29 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.